These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1665568)

  • 1. Effects of antiplatelet agents on platelet aggregation induced by platelet--activating factor (PAF) in human whole blood.
    Chan WP; Levy JV
    Prostaglandins; 1991 Oct; 42(4):337-42. PubMed ID: 1665568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
    Ammit AJ; O'Neill C
    Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
    da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
    Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
    Foster AP; Lees P; Andrews MJ; Cunningham FM
    Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
    Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
    Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
    Montrucchio G; Alloatti G; Mariano F; Lupia E; Lucchina PG; Musso E; Emanuelli G; Camussi G
    Circ Res; 1993 Mar; 72(3):658-70. PubMed ID: 8381725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
    Griffin K; Hong T; Levy JV
    Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
    Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
    Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation.
    Lee LW; Peng HC; Ko WC; Hung WC; Su CH; Lin CH; Huang TF; Yen MH; Sheu JR
    Eur J Pharmacol; 1999 Jan; 364(2-3):239-46. PubMed ID: 9932729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
    Koike H; Imanishi N; Natsume Y; Morooka S
    Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
    Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
    Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
    Salari H; Dryden P; Howard S; Bittman R
    Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L; Floch A; Mondot S; Cavero I
    Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking.
    Lehr HA; Weyrich AS; Saetzler RK; Jurek A; Arfors KE; Zimmerman GA; Prescott SM; McIntyre TM
    J Clin Invest; 1997 May; 99(10):2358-64. PubMed ID: 9153277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
    Grigoriadis G; Stewart AG
    Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effect of Web 2086 (Paf antagonist) and ketoprofen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine.
    Bastos da Silva M; Herion F; Raskinet R; David JL; Gustin P; Lekeux P
    Zentralbl Veterinarmed A; 1997 Apr; 44(2):65-71. PubMed ID: 9284631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.